about
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerTrastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesCapecitabine and oxaliplatin for advanced esophagogastric cancer.Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies GrThe genomic landscape of oesophagogastric junctional adenocarcinoma.Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience.Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.Role of erlotinib in the management of pancreatic cancer.Second-line therapy for advanced colorectal carcinoma.Cetuximab in previously treated colorectal cancer.Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey.Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma.Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.Survival from cancer of the pancreas in England and Wales up to 2001Pharmacotherapy for oesophagogastric cancer.miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trialA phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinomaLiposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.Pancreatic neuroendocrine tumors: a review.Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.Current and Future Therapies for Advanced Gastric Cancer.Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.Targeting deficient DNA damage repair in gastric cancer.Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging.Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010.Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer.Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies.Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
P50
Q24649684-C8E21C94-9F32-4355-99A2-8766AF8782B4Q28077666-AA6A40C4-DA03-4DAE-9574-368D96A3B84CQ33313072-175AAD36-BBDE-429A-A2C3-3F074FD20CF4Q33350085-465C9003-EE8E-4762-9F93-B74B7C2348C1Q33380084-BDFB0CD8-B8AE-495D-B161-88BEAB9421C2Q33396215-64843E2B-C436-47B2-BA55-966713B7D8D8Q33435794-0CA77420-B732-4050-94E1-05C60E4EE329Q34389892-D03F6A61-D9C6-4EC2-8E36-E765BEF74025Q35008768-58FE320D-25E3-4D1C-A857-2D3DEC41CEAFQ35799398-0EA76133-920B-465E-8E1F-9BC9CFCF8AC0Q35919264-F9113CC3-0FC2-4410-B1CE-6261C2E87F6BQ36104931-0739D267-AA39-4A22-A7DE-990D542FCBFEQ36116565-CF02E014-769D-412F-8B7C-F1DA1C3225F6Q36446227-FB688EC9-4751-4F12-8F36-60983BC56CFCQ36579220-2C57B209-1DCE-485C-8601-886E20064A6AQ36610277-02666005-3768-439D-A57E-E303E07E3EA5Q36917717-AF0BA315-C832-4040-AA50-8FA92158ED3FQ37011966-F26763A0-5EC3-4D6B-80C8-73D3F3BCA60CQ37022260-2BB8A89C-09B4-48BF-AFA6-D6FDA9D207F4Q37225713-AC572CD2-DE69-467A-8262-076FBEADD17EQ37698616-451E1441-212E-48BD-A788-B44D96443807Q38228522-083CC107-BB09-488B-9E87-F353DA655878Q38372459-E054F1E4-9152-4347-8408-2D2695CA02F6Q38447314-914768D0-8936-4ECF-AFBE-797043881C5CQ38622521-6A43393E-57E1-466B-8CF1-FD9B115DA9ACQ38633265-4F86C2C8-D078-441C-8A29-AB56351AC6ABQ38834760-DEC91C50-CB0B-4B78-99DB-4130818B2C81Q39289539-FBCA4259-B72C-4744-B371-32B8EEA39871Q40086094-6D40571B-260A-42CB-A51A-6A43AC3D3C5EQ41146331-CCC43F1D-1B62-445F-AB1E-3532CB76AC76Q41447028-92BAB166-7065-43CF-8440-12DB57D32558Q42661688-151391AC-8B68-40B1-896B-F92CE3C5B70CQ42959645-2B7FEFB2-E3CE-4249-96E9-1FA3B43B224FQ43254498-C3E5C51B-1E73-4BDB-A0FD-EF324BA255D8Q47384601-502B6DC0-ACD0-42DC-B717-4C63CB3D257FQ47582754-66C26819-AA88-46FF-9B59-EB2693766939Q49836611-B4F20B7D-CA15-481D-9AAF-8E119EE89CE4Q50089660-55067D7B-806A-4ACC-8FD0-479BCF756B6AQ52905730-0FBEDA37-0E94-4BF7-B33B-76512D611732Q53280066-564148A8-D4F0-4511-A6AA-7B3E824F1558
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1496-6792
@en
name
Naureen Starling
@ast
Naureen Starling
@en
Naureen Starling
@es
Naureen Starling
@nl
type
label
Naureen Starling
@ast
Naureen Starling
@en
Naureen Starling
@es
Naureen Starling
@nl
prefLabel
Naureen Starling
@ast
Naureen Starling
@en
Naureen Starling
@es
Naureen Starling
@nl
P106
P31
P496
0000-0002-1496-6792